



## Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

April 25, 2025

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Apr. 25, 2025-- Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.

### Mini-Oral Presentation Details:

**Title:** Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)

**Presenter:** Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center

**Session:** Innovative Approaches to Key Molecular Targets

**Session Date and Time:** Tuesday, April 29 from 2:30-4:30 p.m. CT

**Location:** Room S406 (Vista Ballroom)

**Abstract Number:** CT262

**Title:** The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models

**Presenter:** John M. Maris, MD, Children's Hospital of Philadelphia

**Session:** Advancing the Science of Childhood Cancers: From Bench to Bedside

**Session Date and Time:** Sunday, April 27 from 3:00-5:00 p.m. CT

**Location:** Room E353 C

**Abstract Number:** 1201

### Poster Presentation Details:

**Title:** A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma

**Presenter:** Michal Zimmermann, PhD, Repare Therapeutics

**Session:** Cell Cycle Effects of Anticancer Drugs

**Session Date and Time:** Sunday, April 27 from 2:00-5:00 p.m. CT

**Location:** Poster Section 17

**Poster Number:** 9

**Abstract Number:** 365

**Title:** RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors

**Presenter:** Anne Roulston, PhD, Repare Therapeutics

**Session:** Kinase and Phosphatase Inhibitors 1

**Session Date and Time:** Monday, April 28 from 9:00 a.m.-12:00 p.m. CT

**Location:** Poster Section 21

**Poster Number:** 9

**Abstract Number:** 1734

**Title:** Pan-cancer analysis of *TRIM37* copy-number and development of fit-for-screening in situ hybridization tools

**Presenter:** Isabel Soria-Bretones, PhD, Repare Therapeutics

**Session:** Diagnostic Biomarkers 2

**Session Date and Time:** Sunday, April 27 from 2:00-5:00 p.m. CT

**Location:** Poster Section 31

**Poster Number:** 2

**Abstract Number:** 717

**Title:** Targeting *CCNE1* amplification in gastric cancer

**Presenter:** Sung Joo Jang, Columbia University Irving Medical Center

**Session:** Protein Kinases and Phosphatases as Targets for Therapy

**Session Date and Time:** Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT

**Location:** Poster Section 24

**Poster Number:** 4

**Abstract Number:** 6942

A copy of each poster presentation is available on the [Scientific Resources](#) page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the [Scientific Resources](#) page of the Repare Therapeutics website at the start of each mini-oral session.

### About Repare Therapeutics Inc.

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx<sup>®</sup> platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit

[www.reparerx.com](http://www.reparerx.com) and follow @Reparerx on X (formerly Twitter) and LinkedIn.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250425074570/en/): <https://www.businesswire.com/news/home/20250425074570/en/>

**Investor Relations & Media Contact:**

Matthew DeYoung

Investor Relations and Media

Argot Partners

[investors@reparerx.com](mailto:investors@reparerx.com)

Source: Repare Therapeutics Inc.